Wednesday, August 28, 2024

Interplay of FXN expression and lipolysis in white adipocytes plays a critical role in insulin sensitivity in Friedreich’s ataxia mouse model

›
Wu, L., Huang, F., Yang, L. et al. Interplay of FXN expression and lipolysis in white adipocytes plays a critical role in insulin sensitivit...
Friday, August 23, 2024

A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia

›
Valentine Mosbach, Hélène Puccio, A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia, Biochimi...

NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich’s Ataxia

›
NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich’s Ataxia, Caroline E. Perry, … , David R. Lyn...
Sunday, August 18, 2024

Emerging therapies in hereditary ataxias

›
Eisel MLS, Burns M, Ashizawa T, Byrne B, Corti M, Subramony SH. Emerging therapies in hereditary ataxias. Trends Mol Med. August 16, 2024 ;0...
Tuesday, August 13, 2024

The importance of synthetic pharmacotherapy for recessive cerebellar ataxias

›
Beaudin, M., Dupre, N., & Manto, M. (2024). The importance of synthetic pharmacotherapy for recessive cerebellar ataxias. Expert Review ...

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

›
NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. “Based on the favorable evidence to date, we have initiated engagements...
Saturday, August 10, 2024

Everything You Need to Know About Larimar Therapeutics' Nomlabofusp and the FDA's START Program

›
August 7, 2024 By Andrew Cox, Pharm.D., MBA. www.managedhealthcareexecutive.com  Nomlabofusp is a protein replacement therapy designed to de...

Lexeo Therapeutics' LX2006 Shows Promise in Treating Friedreich Ataxia Cardiomyopathy

›
August 9, 2024. By Andrew Cox, Pharm.D., MBA. Managed Healthcare Executive. Although the initial results are promising, LX2006's ultimat...

New and Emerging Drug and Gene Therapies for Friedreich Ataxia

›
Scott V, Delatycki MB, Tai G, Corben LA. New and Emerging Drug and Gene Therapies for Friedreich Ataxia. CNS Drugs. 2024 Aug 8. doi: 10.1007...
Thursday, August 8, 2024

Glial cell activation precedes neurodegeneration in the cerebellar cortex of the YG8–800 murine model of Friedreich ataxia

›
Andrés Vicente-Acosta, Saúl Herranz-Martín, María Ruth Pazos, Jorge Galán-Cruz, Mario Amores, Frida Loria, Javier Díaz-Nido, Glial cell acti...